FIELD: medicine; endocrinology.
SUBSTANCE: invention relates to medicine, namely to endocrinology, it can be used for body weight reduction, obesity treatment, appetite suppression or acceleration of a weight loss in a human subject. At least one osmotic delivery device containing exenatide is implanted in a human subject for providing continuous exenatide injection from at least one osmotic delivery device, wherein continuous injection includes the first period of continuous exenatide injection in the first doze with the following second period of continuous exenatide injection in the second doze, while the specified second doze is greater than the first doze. Stable exenatide delivery in therapeutic concentration is achieved during 5 days after each implantation of osmotic delivery device. Stable exenatide delivery is continuous during at least 3 months.
EFFECT: body weight reduction and tolerance of high doses of exenatide are achieved due to the increase in exenatide doze during extended phase of its injection.
28 cl, 21 dwg, 20 tbl, 4 ex
